Abstract:DPAGT1-CDG is a Congenital Disorder of Glycosylation (CDG) that lacks effective therapies. It is caused by mutations in the gene DPAGT1 which encodes the first enzyme in N-linked glycosylation. We used a Drosophila rough eye model of DPAGT1-CDG with an improperly developed, small eye phenotype. We performed a drug repurposing screen on this model using 1,520 small molecules that are 98% FDA/EMA-approved to find drugs that improved its eye. We identified 42 candidate drugs that improved the DPAGT1-CDG model. Notably from this screen, we found that pharmacological and genetic inhibition of the dopamine D2 receptor partially rescued the DPAGT1-CDG model. Loss of both dopamine synthesis and recycling partially rescued the model, suggesting that dopaminergic flux and subsequent binding to D2 receptors is detrimental under DPAGT1 deficiency. This links dopamine signaling to N-glycosylation and represents a new potential therapeutic target for treating DPAGT1-CDG. We also genetically validate other top drug categories including acetylcholine-related drugs, COX inhibitors, and an inhibitor of NKCC1. These drugs and subsequent analyses reveal novel biology in DPAGT1 mechanisms, and they may represent new therapeutic options for DPAGT1-CDG. Some proteins require the attachment of sugars—like mannose and galactose—in order to perform their function. The process that attaches these sugars is called "glycosylation". Genetic mutations in glycosylation pathways cause Congenital Disorders of Glycosylation ("CDGs"). CDGs are devastating disorders causing a multitude of symptoms, including seizures and developmental delay, and they have few treatment options. We wanted to find new potential treatment options for the CDG called DPAGT1-CDG. We use a model of DPAGT1-CDG that has inhibited glycosylation resulting in impaired eye development. We used a "drug repurposing screen", where we screened 1,520 drugs that are 99% FDA- or EMA-approved, to find drugs that improved its eye. We found 42 drug hits, including classes like dopamine receptor inhibitors, NSAIDs, and antihistamines. We found that the dopamine receptor inhibitors caused the strongest improvement. In addition, genetically impairing multiple parts of the dopamine pathway (e.g. how dopamine is made or recycled) also improved the model. This suggests that dopamine signaling is important in DPAGT1-CDG, and it could represent a new therapeutic option for patients. Overall, we present validation of several of our drugs, and these represent potential new treatments while also improving our understanding of glycosylation.

A drug repurposing screen reveals dopamine signaling as a critical pathway underlying potential therapeutics for the rare disease DPAGT1-CDG

A drug repurposing screen reveals dopamine signaling as a critical pathway underlying potential therapeutics for the rare disease DPAGT1-CDG

A new patient‐derived iPSC model for dystroglycanopathies validates a compound that increases glycosylation of α‐dystroglycan

Functional Prediction of the Potential NGLY1 Mutations Associated with Rare Disease CDG

Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG

Modeling Congenital Disorders of N-Linked Glycoprotein Glycosylation in Drosophila melanogaster

Prospective phenotyping of NGLY1-CDDG, the first congenital disorder of deglycosylation

Identification of potential modulators for human GPD1 by docking-based virtual screening, molecular dynamics simulations, binding free energy calculations, and DeLA-drug analysis

Targeting AGAT gene expression – a drug screening approach for the treatment of GAMT deficiency

(Key1-001) congenital disorders of glycosylation: Glycobiology at the bedside

Metabolic Rewiring and Altered Glial Differentiation in an iPSC-Derived Astrocyte Model Derived from a Nonketotic Hyperglycinemia Patient

Cardiac glycosides restore autophagy flux in an iPSC-derived neuronal model of WDR45 deficiency

AAV-mediated expression of mouse or human GLDC normalises metabolic biomarkers in a GLDC-deficient mouse model of Non-Ketotic Hyperglycinemia

The impact of place and time on the proportion of late-stage diagnosis: the case of prostate cancer in Florida, 1981-2007.

The syndrome of ectrodactyly, ectodermal dysplasia and cleft lip and palate: report of a family demonstrating a dominant inheritance pattern

Genetic screening and metabolomics identify glial adenosine metabolism as a therapeutic target in Parkinson's disease

Identification of CNTN2 as a genetic modifier of PIGA-CDG through pedigree analysis of a family with incomplete penetrance and functional testing in Drosophila

Pertussis immunization in a high-risk postpartum population.

Evaluation of utilisation of health workers for secondary prevention of oral cancer in Kerala, India.

Aberrant N-glycosylation is a therapeutic target in carriers of a common and highly pleiotropic mutation in the manganese transporter ZIP8

mRNA therapy restores euglycemia and prevents liver tumors in murine model of glycogen storage disease